PubMed Health⌕ Search

PubMed · 16450232

Practice patterns in sildenafil prescribing.

Abstract

BACKGROUND: This study explores the incorporation of sildenafil into treatment of the common conditions of psychosexual and erectile dysfunction (ED). METHODS: The 2002 National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey were analyzed for visits in which sildenafil was prescribed. Patient, visit, and provider characteristics for visits in which sildenafil was prescribed were compared between visits that documented a presenting complaint or diagnosis consistent with ED and those without documentation consistent with ED. RESULTS: Of visits by men 30 years or older receiving sildenafil, 50% had no documented presenting complaint or diagnosis consistent with ED. No significant differences were found between those prescribed sildenafil with or without a reason for visit or diagnosis of ED based on age, race, or payment type. Individuals with more visits in the last 12 months were significantly less likely to have a recorded diagnosis consistent with ED. Urologists documented ED significantly more often than family medicine, internal medicine, and other physicians. CONCLUSIONS: Sildenafil is being prescribed at a significant number of visits without documentation of a reason for visit or diagnosis consistent with psychosexual or erectile dysfunction.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sara E Young, Arch G Mainous, Vanessa A Diaz, Charles J Everett. 2006. Practice patterns in sildenafil prescribing.. https://pubmed.ncbi.nlm.nih.gov/16450232/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.

Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, vardenafil, or tadalafil) or phosphorylation by cyclic nucleotide-dependent protein kinase causes an apparent conformational change in PDE5, as indicated by a shift in migration on non-denaturing PAGE gels and an altered pattern of tryptic digestion. Combination of cGMP and a PDE5 inhibitor or phosphorylation does not cause a further gel shift or change in tryptic digest. Phosphorylation of PDE5 is stimulated by inhibitors, and combination of cGMP and inhibitor does not cause further phosphorylation. Dephosphorylation of PDE5 by either purified phosphoprotein phosphatase-1 or -2A catalytic subunit or by a crude phosphatase mixture is not affected by cGMP or inhibitors, suggesting that phosphorylation itself maintains conformational exposure of the phosphorylation site. The combined results imply that cGMP binding to the catalytic site initiates negative feedback control of many cellular cGMP signaling pathways by directly stimulating phosphorylation and activation of PDE5; by exploiting this molecular mechanism, PDE5 inhibitors stimulate their own potencies.

3',5'-Cyclic-GMP Phosphodiesterases↗

Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.

The diagnosis and treatment of erectile dysfunction has changed dramatically since the availability of safe and effective oral therapies. Unfortunately, not all men can be adequately treated in this way, and might require more invasive testing to diagnose and treat the specific cause of their dysfunction. This review looks at the tests and strategies available for men who cannot be treated by oral therapy alone.

3',5'-Cyclic-GMP Phosphodiesterases↗